Results 41 to 50 of about 14,756 (228)
Frontiers in Immunology, 2018 Background: Bullous pemphigoid is a subepidermal blistering skin disease, associated with autoantibodies to hemidesmosomal proteins, complement activation at the dermal-epidermal junction, and dermal granulocyte infiltration.
Roxana M. Chiorean +9 more
doaj +1 more source
Autoimmune Bullous Diseases in Childhood
, 2022 Autoimmune bullous diseases (AIBDs) rarely occur in childhood and in contrast to the chronic disease course in adults, often have a milder clinical course, a better treatment response and better prognosis. Although literature is scarce, several case reports and case series describe childhood cases of linear IgA disease, bullous pemphigoid, dermatitis ...
Bolling, Maria C., Meijer, Joost M.
openaire +2 more sources
AUTOIMMUNE BULLOUS DERMATOSES. DIFFERENTIAL DIAGNOSIS
Vestnik Dermatologii i Venerologii, 2017 The review presents modern ideas concerning autoimmune bullous dermatoses (pemphigoid group): Duhring disease, bullous pemphigoid, cicatrizing pemphigus, pemphigoid gestationis, linear IgA bullous dermatosis and acquired bullous epidermolysis ...
V. I. Al'banova, M. A. Nefedova
doaj +1 more source
Mast Cell Regulation of the Immune Response [PDF]
, 2009 Mast cells are well known as principle effector cells of type I hypersensitivity responses. Beyond this role in allergic disease, these cells are now appreciated as playing an important role in many inflammatory conditions.
Johanna K. Morales +4 more
core +2 more sources
Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. [PDF]
PLoS ONE, 2015 Coagulation activation has been demonstrated in two prototypic autoimmune skin diseases, chronic autoimmune urticaria and bullous pemphigoid, but only the latter is associated with increased thrombotic risk.
Massimo Cugno +9 more
doaj +1 more source
Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis
Frontiers in Medicine, 2022 BackgroundBullous pemphigoid (BP) is the most common autoimmune-blistering disease, clinically characterized by erythematous urticarial plaques, blisters, and intense pruritus, induced by autoantibodies against two proteins of the dermo-epidermal ...
Francesco Moro +7 more
doaj +1 more source
Dupilumab for bullous pemphigoid with intractable pruritus [PDF]
, 2019 Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Eichenfield, Dawn Z +2 more
core
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Autoimmune diseases and their manifestations on oral cavity: diagnosis and clinical management [PDF]
, 2018 Oral signs are frequently the first manifestation of autoimmune diseases. For this reason, dentists play an important role in the detection of emerging autoimmune pathologies.
Bossù, Maurizio +5 more
core +2 more sources
Successful treatment of eosinophilic esophagitis with upadacitinib prescribed for atopic dermatitis
JPGN Reports, EarlyView.Abstract We describe a pediatric patient treated with upadacitinib for atopic dermatitis (AD) who subsequently achieved sustained clinical and histologic remission of eosinophilic esophagitis (EoE). Upadacitinib is an oral small molecule selective Janus kinase 1 inhibitor that inhibits janus kinase‐signal transduction and activation of transcription ...
Nathalie Nguyen, Maureen Bauer
wiley +1 more source